These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27653543)

  • 21. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.
    Liu W; Zou P; Ding J; Lu Y; Chen YH
    Microbes Infect; 2005 Feb; 7(2):171-7. PubMed ID: 15777646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
    Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
    Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.
    Zharikova D; Mozdzanowska K; Feng J; Zhang M; Gerhard W
    J Virol; 2005 Jun; 79(11):6644-54. PubMed ID: 15890902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
    Tao W; Gill HS
    Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An influenza A virus vaccine based on an M2e-modified alphavirus.
    Krishnavajhala HR; Williams J; Heidner H
    Arch Virol; 2018 Feb; 163(2):483-488. PubMed ID: 29079954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
    Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
    Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Universal influenza A vaccine: optimization of M2-based constructs.
    De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
    Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
    Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
    Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
    Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Yang WT; Yang GL; Wang Q; Huang HB; Jiang YL; Shi CW; Wang JZ; Huang KY; Jin YB; Wang CF
    Antiviral Res; 2017 Feb; 138():9-21. PubMed ID: 27908830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine options for influenza: thinking small.
    Schepens B; De Vlieger D; Saelens X
    Curr Opin Immunol; 2018 Aug; 53():22-29. PubMed ID: 29631195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.
    Chen N; Gallovic MD; Tiet P; Ting JP; Ainslie KM; Bachelder EM
    J Control Release; 2018 Nov; 289():114-124. PubMed ID: 30261204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
    Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D
    Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
    Turley CB; Rupp RE; Johnson C; Taylor DN; Wolfson J; Tussey L; Kavita U; Stanberry L; Shaw A
    Vaccine; 2011 Jul; 29(32):5145-52. PubMed ID: 21624416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.